280 related articles for article (PubMed ID: 15642810)
1. Penetration pharmacokinetics of topically administered 0.5% moxifloxacin ophthalmic solution in human aqueous and vitreous.
Hariprasad SM; Blinder KJ; Shah GK; Apte RS; Rosenblatt B; Holekamp NM; Thomas MA; Mieler WF; Chi J; Prince RA
Arch Ophthalmol; 2005 Jan; 123(1):39-44. PubMed ID: 15642810
[TBL] [Abstract][Full Text] [Related]
2. Vitreous and aqueous penetration of orally administered moxifloxacin in humans.
Vedantham V; Lalitha P; Velpandian T; Ghose S; Mahalakshmi R; Ramasamy K
Eye (Lond); 2006 Nov; 20(11):1273-8. PubMed ID: 16200061
[TBL] [Abstract][Full Text] [Related]
3. Vitreous and aqueous penetration of orally administered moxifloxacin in humans.
Hariprasad SM; Shah GK; Mieler WF; Feiner L; Blinder KJ; Holekamp NM; Gao H; Prince RA
Arch Ophthalmol; 2006 Feb; 124(2):178-82. PubMed ID: 16476886
[TBL] [Abstract][Full Text] [Related]
4. Human intraocular penetration pharmacokinetics of moxifloxacin 0.5% via topical and collagen shield routes of administration.
Hariprasad SM; Mieler WE; Shah GK; Blinder KJ; Apte RS; Holekamp NM; Thomas MA; Chi J; Prince RA
Trans Am Ophthalmol Soc; 2004; 102():149-55; discussion 155-7. PubMed ID: 15747753
[TBL] [Abstract][Full Text] [Related]
5. Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device.
Hariprasad SM; Shah GK; Chi J; Prince RA
J Cataract Refract Surg; 2005 Nov; 31(11):2142-6. PubMed ID: 16412929
[TBL] [Abstract][Full Text] [Related]
6. Differential aqueous and vitreous concentrations of moxifloxacin and ofloxacin after topical administration one hour before vitrectomy.
Lai WW; Chu KO; Chan KP; Choy KW; Wang CC; Tsang CW; Pang CP
Am J Ophthalmol; 2007 Aug; 144(2):315-8. PubMed ID: 17659971
[TBL] [Abstract][Full Text] [Related]
7. The effect of cataract surgery on ocular levels of topical moxifloxacin.
Mather R; Stewart JM; Prabriputaloong T; Wong J; McLeod SD
Am J Ophthalmol; 2004 Oct; 138(4):554-9. PubMed ID: 15488780
[TBL] [Abstract][Full Text] [Related]
8. Fourth-generation fluoroquinolone penetration into the aqueous humor in humans.
McCulley JP; Caudle D; Aronowicz JD; Shine WE
Ophthalmology; 2006 Jun; 113(6):955-9. PubMed ID: 16603244
[TBL] [Abstract][Full Text] [Related]
9. Vitreous penetration of topical moxifloxacin and gatifloxacin in humans.
Costello P; Bakri SJ; Beer PM; Singh RJ; Falk NS; Peters GB; Melendez JA
Retina; 2006 Feb; 26(2):191-5. PubMed ID: 16467677
[TBL] [Abstract][Full Text] [Related]
10. Aqueous penetration and biological activity of moxifloxacin 0.5% ophthalmic solution and gatifloxacin 0.3% solution in cataract surgery patients.
Kim DH; Stark WJ; O'Brien TP; Dick JD
Ophthalmology; 2005 Nov; 112(11):1992-6. PubMed ID: 16183125
[TBL] [Abstract][Full Text] [Related]
11. Human aqueous humor concentrations of besifloxacin, moxifloxacin, and gatifloxacin after topical ocular application.
Donnenfeld ED; Comstock TL; Proksch JW
J Cataract Refract Surg; 2011 Jun; 37(6):1082-9. PubMed ID: 21596251
[TBL] [Abstract][Full Text] [Related]
12. Vitreous penetration of orally administered gatifloxacin in humans.
Hariprasad SM; Mieler WF; Holz ER
Trans Am Ophthalmol Soc; 2002; 100():153-9. PubMed ID: 12545689
[TBL] [Abstract][Full Text] [Related]
13. Vitreous and aqueous penetration of orally and topically administered moxifloxacin.
Fukuda M; Shibata N; Osada H; Yamashiro Y; Sasaki H
Ophthalmic Res; 2011; 46(3):113-7. PubMed ID: 21325873
[TBL] [Abstract][Full Text] [Related]
14. Vitreous and aqueous penetration of orally administered gatifloxacin in humans.
Hariprasad SM; Mieler WF; Holz ER
Arch Ophthalmol; 2003 Mar; 121(3):345-50. PubMed ID: 12617704
[TBL] [Abstract][Full Text] [Related]
15. Aqueous and vitreous concentrations following topical administration of 1% voriconazole in humans.
Vemulakonda GA; Hariprasad SM; Mieler WF; Prince RA; Shah GK; Van Gelder RN
Arch Ophthalmol; 2008 Jan; 126(1):18-22. PubMed ID: 18195213
[TBL] [Abstract][Full Text] [Related]
16. Determination of vitreous, aqueous, and plasma concentration of orally administered voriconazole in humans.
Hariprasad SM; Mieler WF; Holz ER; Gao H; Kim JE; Chi J; Prince RA
Arch Ophthalmol; 2004 Jan; 122(1):42-7. PubMed ID: 14718293
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 2 moxifloxacin regimens for preoperative prophylaxis: prospective randomized triple-masked trial. Part 1: aqueous concentration of moxifloxacin.
Vasavada AR; Gajjar D; Raj SM; Vasavada V; Vasavada V
J Cataract Refract Surg; 2008 Aug; 34(8):1379-82. PubMed ID: 18655991
[TBL] [Abstract][Full Text] [Related]
18. Ocular penetration and pharmacokinetics of topical gatifloxacin 0.3% and moxifloxacin 0.5% ophthalmic solutions after keratoplasty.
Holland EJ; Lane SS; Kim T; Raizman M; Dunn S
Cornea; 2008 Apr; 27(3):314-9. PubMed ID: 18362660
[TBL] [Abstract][Full Text] [Related]
19. Aqueous humor penetration of gatifloxacin and moxifloxacin eyedrops given by different methods before cataract surgery.
Ong-Tone L
J Cataract Refract Surg; 2007 Jan; 33(1):59-62. PubMed ID: 17189794
[TBL] [Abstract][Full Text] [Related]
20. Aqueous penetration of orally and topically administered moxifloxacin.
Sharma T; Kamath MM; Kamath MG; Nayak RR; Bairy KL; Musmade PB
Br J Ophthalmol; 2015 Sep; 99(9):1182-5. PubMed ID: 25824259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
